The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. - Wikidata - wikimedia - TriplyDB

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.

http://www.wikidata.org/entity/Q36828156

about

Screening for antifungal peptides and their modes of action in Aspergillus nidulans.Echinocandins: the newest class of antifungals.Development and validation of an in vivo Candida albicans biofilm denture model.In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction.Current perspectives on echinocandin class drugs.Safety and interactions of new antifungals in stem cell transplant recipients.Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model.Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.Synthesis and antifungal activities of glycosylated derivatives of the cyclic peptide fungicide caspofungin.Antifungal management practices in liver transplant recipients.Significantly Improved Pharmacokinetics Enhances Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis

P2860

Q33690395-6D158930-9325-4C52-A4B8-6F7442BF7094 Q34019188-691DBC0B-C254-4E7A-9963-AFEBD3293169 Q34119405-0FF64782-93FA-4A23-96B4-C51270295828 Q34211108-AC276FBB-3408-44DB-8562-0AEC7ACD50AE Q35941237-559CCA9E-C0DB-49EB-BC10-CA42960546A9 Q36004967-3CF2FA4C-BAA0-464E-AB4E-8B97E474FAFD Q37554055-69B1A510-A4AF-4A00-B755-5310B228D192 Q38036740-94EC2FAB-3471-4B86-8F3F-1E58956000EA Q40121744-B795F626-CD3D-4C9C-A486-D97CCB835123 Q41787736-11EAC3EB-B61F-4643-8E4A-28B4B1438A2A Q42720364-582F4C09-D4D3-48B7-97E0-7FEECFF0E128 Q43698008-CF4C063C-3E90-4738-A671-EC6FBD573B62 Q46812014-4EE01048-985D-4352-A06F-60FE926C82B8 Q58701121-51F7933F-E3A8-444A-B712-099EDD580A9C

P2860

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.

http://www.wikidata.org/entity/Q36828156

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

The echinocandin micafungin: a ...... clinical efficacy and safety.

@en

type

label

The echinocandin micafungin: a ...... clinical efficacy and safety.

@en

prefLabel

The echinocandin micafungin: a ...... clinical efficacy and safety.

@en

P1433

Q36828156-5B3CFCB5-03CD-4D04-A686-2DAE3AC23C69

P1476

Q36828156-E38F1A25-35D6-4957-A413-B0261CA350FC

P2093

Q36828156-574016F5-3759-4100-B7A8-07010D40A80F

Q36828156-BEFF8FA3-CC67-465F-AE06-644B94076FB6

P2860

Q36828156-0027E34B-347B-4982-B9F8-043BB4DEBFD2

Q36828156-07BC7C92-6C33-4B81-A2B7-5693B3F1544D

Q36828156-094846C8-B7FE-44BB-8006-4B4E6848F83A

Q36828156-0A6F59A1-C040-4B61-8F39-0ECEEE2F8A82

Q36828156-0ADF308F-2A54-4255-B7F3-E63517D1E946

Q36828156-0DFBB783-A595-48F2-B17C-5D0706324DC6

Q36828156-11603333-8395-499A-8B7B-0096D2E4AADD

Q36828156-12A40596-F7FF-481E-BBCD-1E4C18DC1D09

Q36828156-1312B66E-4777-4228-B633-5DE1ECE6ACC3

Q36828156-1D3BA051-1203-4E10-8D9E-A8A598486AB7

P304

Q36828156-47F7F55E-39D5-4086-A167-FBAFDBA18233

P31

Q36828156-0C026F9A-5B27-457C-926B-4B2AA5D066A1

P356

Q36828156-C834559D-EC7E-4D9B-875E-9048D618D55D

P407

Q36828156-64D11116-F182-49A9-9062-8F1B14455B8D

P433

Q36828156-F3E94250-ADCF-49A8-A2C1-8378B5BD73C3

P478

Q36828156-F2469AD4-833D-469C-8A09-61D56C0CBC82

P577

Q36828156-46B64A1A-587E-4E18-9CE2-1BD68F3A897E

P698

Q36828156-FEBCA0A7-CD40-442C-8268-DB1BF1BBC17F

P356

14656566.8.8.1155

P1433

Expert Opinion on Pharmacotherapy

P1476

The echinocandin micafungin: a ...... clinical efficacy and safety.

@en

P2093

James S Lewis

http://www.w3.org/2001/XMLSchema#string

Nathan P Wiederhold

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Epidemiology of invasive candidiasis: a persistent public health problem

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.

P304

1155-1166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.8.8.1155

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17516879

http://www.w3.org/2001/XMLSchema#string